Form 8-K Elevance Health, Inc. For: Jul 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Elevance (ELV) PT Raised to $585 at RBC Capital
July 18, 2024 6:13 AM EDTRBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $585.00 (from $575.00) while maintaining a Outperform rating.
The analyst comments "We believe ELV shares are oversold on known temporary Medicaid mix headwinds (which should ease over the next 612 months) and DCP optics... More
Morgan Stanley Reiterates Overweight Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $643.00 price target on Elevance (NYSE: ELV).
The analyst comments "Pre-Call View - ELV Shares Should Grind higher on Consolidated MLR Beat: While we await conf. call granularity on underlying cost trends by line of business, however, the... More
Truist Securities Reiterates Buy Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTTruist Securities analyst David MacDonald reiterated a Buy rating and $620.00 price target on Elevance (NYSE: ELV).
The analyst comments "First Read Solid 2Q With MLR A Bit Better, Strong Growth At Carelon, FY Guidance Reaffirmed. ELV reported solid 2Q results featuring in-line revenues, MLR that was modestly better than our/consensus estimates and adjusted EPS also topped expectations with FY guidance of at least $37.20 reaffirmed. Operating revenue of $43.22B was roughly in-line with our $43.24BE and consensus $43.05B... More
